ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enhancing pulp regeneration through metabolic reprogramming of mature dental pulp stem cells mediated by GLUT1/HK2 mRNA delivery.International journal of oral science · 2026Article
- Exosome Augmentation Technologies for Drug Delivery and Disease Treatment: A Review.Biomaterials research · 2026Review
- Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lung disease remains a persistent global health challenge. Advances in medical research have led to innovative strategies to combat these conditions, with biomaterials emerging as a promising platform for targeted drug delivery. Various biomaterials-including nanoparticles such as liposomes, polymers, hybrid systems, dendritic polymers, gold nanoparticles, mesoporous silica, calcium carbonate, and exosomes-exhibit excellent biocompatibility. These materials protect therapeutic agents from nuclease degradation, stabilize drug carriers, and enhance cellular uptake via mechanisms such as endocytosis. Chemical modifications further improve biomaterials by facilitating endosomal escape and conjugation with targeting ligands, thereby enabling precise delivery to specific cells or tissues. As a therapeutic modality, mRNA offers high biosafety, notable controllability, efficient translation, and immunomodulatory properties. This review evaluates the impact of lung structure on drug absorption, examines delivery mechanisms associated with various biomaterial types, and presents application examples. It also summarizes recent research developments, discusses clinical limitations, and explores future research directions for biomaterials in lung disease therapy. Additionally, it highlights the role of biomaterials in stabilizing and protecting mRNA, providing insights into the advancement of mRNA-based therapeutics. This review aims to establish a robust theoretical foundation and offer practical guidance for biomaterial-based mRNA therapies in treating lung diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.